Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Increases By 10.7%

Celldex Therapeutics, Inc. (NASDAQ:CLDX) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 8,090,000 shares, an increase of 10.7% from the December 15th total of 7,310,000 shares. Based on an average daily volume of 1,010,000 shares, the short-interest ratio is presently 8.0 days.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CLDX. The Goldman Sachs Group initiated coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price objective for the company. Citigroup initiated coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Thursday, January 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Thursday, December 19th. Finally, Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $62.25.

Insider Activity at Celldex Therapeutics

In other news, CEO Anthony S. Marucci acquired 11,500 shares of Celldex Therapeutics stock in a transaction that occurred on Monday, November 11th. The stock was purchased at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares in the company, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.80% of the stock is owned by insiders.

Institutional Trading of Celldex Therapeutics

A number of hedge funds have recently bought and sold shares of CLDX. American Century Companies Inc. boosted its position in Celldex Therapeutics by 128.5% during the second quarter. American Century Companies Inc. now owns 416,000 shares of the biopharmaceutical company’s stock worth $15,396,000 after acquiring an additional 233,928 shares during the last quarter. HighVista Strategies LLC acquired a new stake in Celldex Therapeutics during the second quarter worth approximately $356,000. Magnetar Financial LLC boosted its position in Celldex Therapeutics by 61.4% during the second quarter. Magnetar Financial LLC now owns 17,390 shares of the biopharmaceutical company’s stock worth $644,000 after acquiring an additional 6,613 shares during the last quarter. Marshall Wace LLP boosted its position in Celldex Therapeutics by 53.3% during the second quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock worth $50,995,000 after acquiring an additional 479,068 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Celldex Therapeutics by 51.0% during the second quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock worth $71,725,000 after acquiring an additional 654,194 shares during the last quarter.

Celldex Therapeutics Stock Up 4.5 %

Shares of CLDX traded up $1.02 during mid-day trading on Friday, reaching $23.78. 854,667 shares of the company’s stock were exchanged, compared to its average volume of 852,336. The company has a 50-day simple moving average of $25.80 and a two-hundred day simple moving average of $31.84. Celldex Therapeutics has a 52-week low of $22.17 and a 52-week high of $53.18. The company has a market cap of $1.58 billion, a price-to-earnings ratio of -9.25 and a beta of 1.62.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.